RCKTW

distress 6/10 · elevated risk

$0.00-3%today-87% from 52w high

Revenue

pre-revenue

Liquidity

$144M

Runway

0.8 yrs

Shares 1y

+1%

Price & events

-86.8% over 6M

CatalystRating changeDilutionFinancingdashed = today

-3.3%

+0.0%

-85.0%

—

-86.8%

All

Overview

Market Cap: $316.66K
Volume: 3.14K
52 Week Range: $0.00 – $0.02
Total Shares: 109.19M
RVOL: 2.52x

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 2

2025-05-23safety signalRP-A501 · Patient experienced serious adverse event (capillary leak syndrome) and subsequently died from acute systemic infectionSEC 8-K
2025-05-23clinical holdRP-A501 · FDA placed clinical hold on Phase 2 trial of RP-A501 for Danon disease after SAE and patient deathSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 109,193,549 · 1 offerings/1y · 0 PIPEs

2026-04-288-Kmaterial_agreement
2026-03-108-Kmaterial_agreement
2026-03-10424B5offering
2026-03-10EFFECTshelf_effective
2026-03-02S-3shelf_registration
2025-09-178-Kmaterial_agreement
2024-12-16SC 13D/Astrategic_stake

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified